Clinical Trial Applications: Filter, Search, and view applications


Clear
Extended search...

Page 4 of 59, showing 5 Applications out of 292 total, starting on record 16, ending on 20

# Protocol No Study Title Investigator(s) & Site(s) Application Status

16.

ECCT/20/07/02   RV 460 HIV Vaccine Trial
    A Randomized, Double-Blind Phase 1 Trial to Evaluate the Safety and Immunogenicity of   Priming with Env-C Plasmid DNA Vaccine Alone, with Different Adjuvants, or with an   Adjuvanted HIV Env gp145 C.6980 Protein Vaccine and Boosting with the Adjuvanted   HIV Env gp145 C.6980 Protein Vaccine with or without the Env-C Plasmid DNA Vaccine   in Healthy HIV Uninfected Adults in Kenya   
Principal Investigator(s)
1. Josphat Kosgei
Site(s) in Kenya
KEMRI/US MRDA-A/K, KERICHO
 
Trial Status Analysing
Protocol Date 29-02-2020
View

17.

ECCT/15/11/05   FALCI Study
    A Randomized, Double-blind, Phase IIb Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of a Single Dose Regimen of Ferroquine (FQ) with Artefenomel (OZ439) in Adults and Children with Uncomplicated Plasmodium falciparum Malaria.   
Principal Investigator(s)
1. Grace Kiringa Kaguthi
Site(s) in Kenya
1. KEMRI Center for Respiratory Diseases Research (Siaya county)
2. KEMRI Walter Reed Kombewa (Kisumu county)
3. KEMRI Kisumu (Kisumu county)
 
Trial Status Recruiting
Protocol Date 20-11-2014
View

18.

ECCT/20/01/01   LEVERAGING THE DEPRESSION AND PRIMARY-CARE PARTNERSHIP FOR EFFECTIVENESS-IMPLEMENTATION RESEARCH
    A SEQUENTIAL, MULTIPLE ASSIGNMENT RANDOMIZED TRIAL (SMART) FOR NON-SPECIALIST TREATMENT OF COMMON MENTAL DISORDERS IN KENYA: LEVERAGING THE DEPRESSION AND PRIMARY-CARE PARTNERSHIP FOR EFFECTIVENESS-IMPLEMENTATION RESEARCH (DAPPER) PROJECT (SMART-DAPPER)           
Principal Investigator(s)
1. Anne Muthoni Mathai
2. Susan Meffert
Site(s) in Kenya
Kisumu County Hospital
 
Trial Status (not set!)
Protocol Date 08-08-2019
View

19.

ECCT/16/05/01   A5338
    A5338   An Open-Label, Non-Randomized Study of Pharmacokinetic Interactions Among   Depot Medroxyprogesterone Acetate (DMPA), Rifampicin (RIF), and Efavirenz   (EFV) in Women Co-Infected with Human Immunodeficiency Virus (HIV) and   Tuberculosis (TB)   
Principal Investigator(s)
1. David Schnabel
Site(s) in Kenya
KISUMU CRS
 
Trial Status Completed
Protocol Date 12-12-2014
View

20.

ECCT/21/03/07   CHIMES
    AN OPEN-LABEL, MULTICENTER STUDY TO ASSESS DISEASE ACTIVITY AND BIOMARKERS OF NEURONAL DAMAGE IN MINORITY PATIENTS WITH RELAPSING MULTIPLE SCLEROSIS RECEIVING TREATMENT WITH OCRELIZUMAB   
Principal Investigator(s)
1. Mansoor Saleh
Site(s) in Kenya
Aga Khan University, Nairobi
 
Trial Status Recruiting
Protocol Date 16-12-2020
View